Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from NRX Pharmaceuticals ( (NRXP) ).
On October 17, 2025, HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, completed the acquisition of a strategic interest in Cohen & Associates, LLC, a leading interventional psychiatry clinic in Florida. This acquisition aims to expand HOPE’s presence in Western Florida and Palm Beach, with Dr. Rebecca Cohen appointed as Medical Director to oversee medical standards and drive growth. The move is expected to enhance HOPE’s revenue and EBITDA, positioning it as a leader in life-transforming therapies for depression and PTSD.
The most recent analyst rating on (NRXP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.
Spark’s Take on NRXP Stock
According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.
NRX Pharmaceuticals is navigating significant financial hurdles with net losses and negative equity, typical for early-stage biotech firms. However, strategic initiatives and drug development progress provide potential upside. Technical analysis and valuation reflect speculative potential, with the stock currently exhibiting mixed technical signals. The positive outlook from the earnings call highlights strategic moves that could improve the company’s financial health if successful.
To see Spark’s full report on NRXP stock, click here.
More about NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company is advancing products like NRX-100 and NRX-101, which have received designations for treating suicidal ideation and bipolar depression. HOPE Therapeutics, a subsidiary, is building a network of interventional psychiatry clinics offering treatments like ketamine and TMS.
Average Trading Volume: 429,663
Technical Sentiment Signal: Buy
Current Market Cap: $76.3M
See more data about NRXP stock on TipRanks’ Stock Analysis page.